Management of excessive anticoagulant effect due to vitamin K antagonists.

Unexpectedly elevated INR values are commonly encountered in clinical practice. In the absence of bleeding, such values may be treated with either simple warfarin withdrawal or the administration of low doses of oral vitamin K. Oral vitamin K will more rapidly return the INR to the therapeutic reference interval; however, its impact on bleeding is unknown. If the INR is in excess of 10, most experts would recommend the administration of vitamin K and, in the case of active bleeding, additional administration of coagulation factors either in the form of fresh frozen plasma (FFP) or prothrombin complex concentrates (PCC). Coagulation factor replacement is required given the need to urgently correct the INR; however, vitamin K should not be forgotten since it is required to antagonize the effect of warfarin, preventing "rebound" anticoagulation after transfused coagulation factors are consumed. This paper will review the evidence supporting various treatment modalities and will provide suggestions for treatment. Future advances in this area will likely focus on evaluations of the relative merits of FFP and PCCs.

[1]  S. Mayer,et al.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. , 2008, The New England journal of medicine.

[2]  C. Leissinger,et al.  Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature , 2008, American journal of hematology.

[3]  S. Mayer,et al.  Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.

[4]  K. Friedman,et al.  Urgent reversal of warfarin with prothrombin complex concentrate , 2006, Journal of thrombosis and haemostasis : JTH.

[5]  E. Hylek,et al.  The risk of hemorrhage among patients with warfarin-associated coagulopathy. , 2006, Journal of the American College of Cardiology.

[6]  J. Weinberger Recombinant activated factor VII for acute intracerebral hemorrhage. , 2006, Current cardiology reports.

[7]  H G Watson,et al.  Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.

[8]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[9]  L. Crane,et al.  Evaluation of Excessive Anticoagulation in a Group Model Health Maintenance Organization , 2006 .

[10]  P. Strengers,et al.  Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. , 2006, Thrombosis research.

[11]  P. O'Malley,et al.  Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. , 2006, Archives of internal medicine.

[12]  W. Ageno,et al.  A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. , 2005, Journal of the American College of Cardiology.

[13]  H. Naritomi,et al.  Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. , 2005, Thrombosis research.

[14]  J. Hanley Warfarin reversal , 2004, Journal of Clinical Pathology.

[15]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[16]  W. V. van Heerde,et al.  Prophylactic effect of recombinant factor VIIa in factor VII deficient patients , 2004, British journal of haematology.

[17]  H. Watson,et al.  Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review , 2004, Canadian Medical Association Journal.

[18]  R. White,et al.  Temporary Reversal of Anticoagulation Using Oral Vitamin K , 2000, Journal of Thrombosis and Thrombolysis.

[19]  R. Zimlichman,,et al.  Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. , 2004, Thrombosis research.

[20]  James Douketis,et al.  Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism , 2003, Annals of Internal Medicine.

[21]  H. Halkin,et al.  Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. , 2003, Archives of internal medicine.

[22]  M. Makris Management of Excessive Anticoagulation or Bleeding , 2003, Seminars in vascular medicine.

[23]  J. C. Sørensen,et al.  Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  David W Bates,et al.  Linking laboratory and pharmacy: opportunities for reducing errors and improving care. , 2003, Archives of internal medicine.

[25]  J. Douketis,et al.  Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin k in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial☆ , 2003 .

[26]  R. Abbate,et al.  Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation. , 2003, Haematologica.

[27]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[28]  David A Fitzmaurice,et al.  ABC of antithrombotic therapy : Bleeding risks of , 2002 .

[29]  G. Volcheck,et al.  The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  H. Naritomi,et al.  Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. , 2002, Thrombosis research.

[31]  D. Garcia,et al.  A survey of oral vitamin K use by anticoagulation clinics. , 2002, Archives of internal medicine.

[32]  J. Douketis,et al.  Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy , 2002, Annals of Internal Medicine.

[33]  S. Kitchen,et al.  Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients , 2002, British journal of haematology.

[34]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[35]  D. Fitzmaurice,et al.  ABC of antithrombotic therapy : Bleeding risks of , 2002 .

[36]  T. Baglin,et al.  Beriplex P/N reverses severe warfarin‐induced overanticoagulation immediately and completely in patients presenting with major bleeding , 2001, British journal of haematology.

[37]  J. Douketis,et al.  Treatment of warfarin-associated coagulopathy: a physician survey. , 2001, Chest.

[38]  M. Makris,et al.  The management of coumarin‐induced over‐anticoagulation , 2001 .

[39]  K. Pendry,et al.  The use of oral vitamin K for reversal of over‐warfarinization , 2001, British journal of haematology.

[40]  M. Makris,et al.  The management of coumarin-induced over-anticoagulation Annotation. , 2001, British journal of haematology.

[41]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.

[42]  J. Douketis,et al.  Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.

[43]  D. Singer,et al.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. , 2000, Archives of internal medicine.

[44]  R. Tait,et al.  A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over‐warfarinization , 2000, British journal of haematology.

[45]  P O Byrne,et al.  Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. , 2000, British journal of neurosurgery.

[46]  R. Kumar,et al.  Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. , 1999, Archives of internal medicine.

[47]  A. Schmaier,et al.  Use of factor IX complex in warfarin-related intracranial hemorrhage. , 1999, Neurosurgery.

[48]  Edward Groth,et al.  Facts and hypotheses , 1999, Nature Biotechnology.

[49]  S. Mörsdorf,et al.  The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. , 1999, Thrombosis research.

[50]  Robert H. Nee,et al.  Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. , 1999, The American journal of cardiology.

[51]  J. Boissel,et al.  The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[52]  M. Crowther,et al.  Low-dose Oral Vitamin K Reliably Reverses Over-anticoagulation due to Warfarin , 1998, Thrombosis and Haemostasis.

[53]  T. Baglin Management of warfarin (coumarin) overdose. , 1998, Blood reviews.

[54]  B. Larke,et al.  Guidelines for red blood cell and plasma transfusion for adults and children. , 1997, The International journal of risk & safety in medicine.

[55]  F. Rosendaal,et al.  Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.

[56]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[57]  C. Harrell,et al.  Oral Vitamin K1: An Option To Reduce Warfarin'S Activity , 1995, The Annals of pharmacotherapy.

[58]  J. Glover,et al.  Conservative treatment of overanticoagulated patients. , 1995, Chest.

[59]  R. Hart,et al.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. , 1995, Stroke.

[60]  E. Garelli,et al.  Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[61]  F. Ala,et al.  Guidelines for the use of fresh frozen plasma , 1992 .

[62]  D. P. Bentley,et al.  Effective Reversal of Warfarin-lnduced Excessive Anticoagulation with Low Dose Mtamin K1 , 1992, Thrombosis and Haemostasis.

[63]  L Goldman,et al.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.

[64]  L. Poller,et al.  Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. , 1976, British medical journal.

[65]  H. Godal,et al.  Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K. , 2009, Acta medica Scandinavica.